Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MiR-4646-5p Acts as a Tumor-Suppressive Factor in Triple Negative Breast Cancer and Targets the Cholesterol Transport Protein GRAMD1B

K. Jonas, F. Prinz, M. Ferracin, K. Krajina, A. Deutsch, T. Madl, B. Rinner, O. Slaby, C. Klec, M. Pichler

. 2023 ; 10 (1) : . [pub] 20231226

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006132

Grantová podpora
DK-MCD W1226 FWF Austrian Science Fund
LX22NPO5102 National Institute for Cancer Research, Next Generation EU, EXCELES
Hertha-Firnberg project FWF Austrian Science Fund
Scholarship Austrian Society of Hemato-Oncology (ÖGHO)

MicroRNAs (miRNAs) are crucial post-transcriptional regulators of gene expression, and their deregulation contributes to many aspects of cancer development and progression. Thus, miRNAs provide insight into oncogenic mechanisms and represent promising targets for new therapeutic approaches. A type of cancer that is still in urgent need of improved treatment options is triple negative breast cancer (TNBC). Therefore, we aimed to characterize a novel miRNA with a potential role in TNBC. Based on a previous study, we selected miR-4646-5p, a miRNA with a still unknown function in breast cancer. We discovered that higher expression of miR-4646-5p in TNBC patients is associated with better survival. In vitro assays showed that miR-4646-5p overexpression reduces growth, proliferation, and migration of TNBC cell lines, whereas inhibition had the opposite effect. Furthermore, we found that miR-4646-5p inhibits the tube formation ability of endothelial cells, which may indicate anti-angiogenic properties. By whole transcriptome analysis, we not only observed that miR-4646-5p downregulates many oncogenic factors, like tumor-promoting cytokines and migration- and invasion-related genes, but were also able to identify a direct target, the GRAM domain-containing protein 1B (GRAMD1B). GRAMD1B is involved in cellular cholesterol transport and its knockdown phenocopied the growth-reducing effects of miR-4646-5p. We thus conclude that GRAMD1B may partly contribute to the diverse tumor-suppressive effects of miR-4646-5p in TNBC.

000      
00000naa a2200000 a 4500
001      
bmc24006132
003      
CZ-PrNML
005      
20240412130911.0
007      
ta
008      
240405s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ncrna10010002 $2 doi
035    __
$a (PubMed)38250802
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Jonas, Katharina $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing, Medical University of Graz, 8010 Graz, Austria $1 https://orcid.org/0000000318559411
245    10
$a MiR-4646-5p Acts as a Tumor-Suppressive Factor in Triple Negative Breast Cancer and Targets the Cholesterol Transport Protein GRAMD1B / $c K. Jonas, F. Prinz, M. Ferracin, K. Krajina, A. Deutsch, T. Madl, B. Rinner, O. Slaby, C. Klec, M. Pichler
520    9_
$a MicroRNAs (miRNAs) are crucial post-transcriptional regulators of gene expression, and their deregulation contributes to many aspects of cancer development and progression. Thus, miRNAs provide insight into oncogenic mechanisms and represent promising targets for new therapeutic approaches. A type of cancer that is still in urgent need of improved treatment options is triple negative breast cancer (TNBC). Therefore, we aimed to characterize a novel miRNA with a potential role in TNBC. Based on a previous study, we selected miR-4646-5p, a miRNA with a still unknown function in breast cancer. We discovered that higher expression of miR-4646-5p in TNBC patients is associated with better survival. In vitro assays showed that miR-4646-5p overexpression reduces growth, proliferation, and migration of TNBC cell lines, whereas inhibition had the opposite effect. Furthermore, we found that miR-4646-5p inhibits the tube formation ability of endothelial cells, which may indicate anti-angiogenic properties. By whole transcriptome analysis, we not only observed that miR-4646-5p downregulates many oncogenic factors, like tumor-promoting cytokines and migration- and invasion-related genes, but were also able to identify a direct target, the GRAM domain-containing protein 1B (GRAMD1B). GRAMD1B is involved in cellular cholesterol transport and its knockdown phenocopied the growth-reducing effects of miR-4646-5p. We thus conclude that GRAMD1B may partly contribute to the diverse tumor-suppressive effects of miR-4646-5p in TNBC.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Prinz, Felix $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing, Medical University of Graz, 8010 Graz, Austria
700    1_
$a Ferracin, Manuela $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy $1 https://orcid.org/0000000215956887
700    1_
$a Krajina, Katarina $u Translational Oncology, II. Med Clinics Hematology and Oncology, 86156 Augsburg, Germany
700    1_
$a Deutsch, Alexander $u Division of Hematology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria $1 https://orcid.org/0000000309142809
700    1_
$a Madl, Tobias $u Division of Molecular Biology & Biochemistry, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria $u BioTechMed-Graz, 8010 Graz, Austria $1 https://orcid.org/0000000297255231
700    1_
$a Rinner, Beate $u Department for Biomedical Research, Medical University of Graz, 8036 Graz, Austria
700    1_
$a Slaby, Ondrej $u Department of Biology, Faculty of Medicine and Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Klec, Christiane $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing, Medical University of Graz, 8010 Graz, Austria $1 https://orcid.org/0000000301958280
700    1_
$a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing, Medical University of Graz, 8010 Graz, Austria $u Translational Oncology, II. Med Clinics Hematology and Oncology, 86156 Augsburg, Germany $1 https://orcid.org/0000000287019462
773    0_
$w MED00198776 $t Non-coding RNA $x 2311-553X $g Roč. 10, č. 1 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38250802 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130904 $b ABA008
999    __
$a ok $b bmc $g 2076139 $s 1215894
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 10 $c 1 $e 20231226 $i 2311-553X $m Non-coding RNA $n Noncoding RNA $x MED00198776
GRA    __
$a DK-MCD W1226 $p FWF Austrian Science Fund
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research, Next Generation EU, EXCELES
GRA    __
$a Hertha-Firnberg project $p FWF Austrian Science Fund
GRA    __
$a Scholarship $p Austrian Society of Hemato-Oncology (ÖGHO)
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Možnosti archivace